Ibis K - Search Results

1

Tirbanibulin (KX2-391) analog KX2-361 inhibits botulinum neurotoxin serotype A mediated SNAP-25 cleavage in pre- and post-intoxication models in cells.

Koc D, Ibis K, Besarat P, Banoglu E, Kiris E. Koc D, et al. Among authors: ibis k. Drug Dev Res. 2024 Sep;85(6):e22248. doi: 10.1002/ddr.22248. Drug Dev Res. 2024. PMID: 39166850

2

The 1,2,3-triazole 'all-in-one' ring system in drug discovery: a good bioisostere, a good pharmacophore, a good linker, and a versatile synthetic tool.

Lengerli D, Ibis K, Nural Y, Banoglu E. Lengerli D, et al. Among authors: ibis k. Expert Opin Drug Discov. 2022 Nov;17(11):1209-1236. doi: 10.1080/17460441.2022.2129613. Epub 2022 Oct 5. Expert Opin Drug Discov. 2022. PMID: 36164263 Review.

3

Synthesis and cellular bioactivities of novel isoxazole derivatives incorporating an arylpiperazine moiety as anticancer agents.

Çalışkan B, Sinoplu E, İbiş K, Akhan Güzelcan E, Çetin Atalay R, Banoglu E. Çalışkan B, et al. Among authors: ibis k. J Enzyme Inhib Med Chem. 2018 Dec;33(1):1352-1361. doi: 10.1080/14756366.2018.1504041. J Enzyme Inhib Med Chem. 2018. PMID: 30251900 Free PMC article.

4

Synthesis and biological evaluation of novel isoxazole-piperazine hybrids as potential anti-cancer agents with inhibitory effect on liver cancer stem cells.

İbiş K, Nalbat E, Çalışkan B, Kahraman DC, Cetin-Atalay R, Banoglu E. İbiş K, et al. Eur J Med Chem. 2021 Oct 5;221:113489. doi: 10.1016/j.ejmech.2021.113489. Epub 2021 Apr 24. Eur J Med Chem. 2021. PMID: 33951549

5

Vicinal Diaryl-Substituted Isoxazole and Pyrazole Derivatives with In Vitro Growth Inhibitory and In Vivo Antitumor Activity.

Turanlı S, Nalbat E, Lengerli D, İbiş K, Güntekin Ergün S, Akhan Güzelcan E, Muyan M, Cetin-Atalay R, Çalışkan B, Banoglu E. Turanlı S, et al. Among authors: ibis k. ACS Omega. 2022 Oct 3;7(41):36206-36226. doi: 10.1021/acsomega.2c03405. eCollection 2022 Oct 18. ACS Omega. 2022. PMID: 36278052 Free PMC article.

6

Benzoxazolone-5-Urea Derivatives as Human Soluble Epoxide Hydrolase (sEH) Inhibitors.

Gur Maz T, Koc B, Jordan PM, İbiş K, Çalışkan B, Werz O, Banoglu E. Gur Maz T, et al. Among authors: ibis k. ACS Omega. 2023 Jan 4;8(2):2445-2454. doi: 10.1021/acsomega.2c06936. eCollection 2023 Jan 17. ACS Omega. 2023. PMID: 36687110 Free PMC article.

7

Targeting TACC3 Induces Immunogenic Cell Death and Enhances T-DM1 Response in HER2-Positive Breast Cancer.

Gedik ME, Saatci O, Oberholtzer N, Uner M, Akbulut Caliskan O, Cetin M, Aras M, Ibis K, Caliskan B, Banoglu E, Wiemann S, Üner A, Aksoy S, Mehrotra S, Sahin O. Gedik ME, et al. Among authors: ibis k. Cancer Res. 2024 May 2;84(9):1475-1490. doi: 10.1158/0008-5472.CAN-23-2812. Cancer Res. 2024. PMID: 38319231 Free PMC article.

8

Reviving immunogenic cell death upon targeting TACC3 enhances T-DM1 response in HER2-positive breast cancer.

Gedik ME, Saatci O, Oberholtzer N, Uner M, Akbulut O, Cetin M, Aras M, Ibis K, Caliskan B, Banoglu E, Wiemann S, Uner A, Aksoy S, Mehrotra S, Sahin O. Gedik ME, et al. Among authors: ibis k. bioRxiv [Preprint]. 2023 Sep 14:2023.09.12.557273. doi: 10.1101/2023.09.12.557273. bioRxiv. 2023. Update in: Cancer Res. 2024 May 2;84(9):1475-1490. doi: 10.1158/0008-5472.CAN-23-2812 PMID: 37745348 Free PMC article. Updated. Preprint.

9

De-Escalation of Nodal Surgery in Clinically Node-Positive Breast Cancer.

Cabioglu N, Koçer HB, Karanlik H, Gülçelik MA, Igci A, Müslümanoglu M, Uras C, Mantoglu B, Trabulus DC, Akgül G, Tükenmez M, Senol K, Özkurt E, Sen E, Karadeniz Çakmak G, Bademler S, Emiroglu S, Yildirim N, Kara H, Dag A, Dilege E, Altinok A, Basaran G, Varol E, Ugurlu Ü, Bölükbasi Y, Ersoy YE, Zengel B, Karaman N, Özbas S, Zer L, Gül Kiliç H, Agcaoglu O, Sakman G, Utkan Z, Soyder A, Akcan A, Ergün S, Yilmaz R, Aydiner A, Soran A, Ibis K, Özmen V. Cabioglu N, et al. Among authors: ibis k. JAMA Surg. 2025 Jan 2. doi: 10.1001/jamasurg.2024.5913. Online ahead of print. JAMA Surg. 2025. PMID: 39745737

10

ASO Author Reflections: Nodal Recurrence Is Rare in Patients with cN+/ycN0 Breast Cancer after Neoadjuvant Chemotherapy Regardless of the Extent of Axillary Surgery or Nodal Pathology in the NEOSENTITURK-Trials MF18-02/18-03 Provided Regional Nodal Irradiation Is Administered.

Cabioglu N, Karanlik H, Igci A, Muslumanoglu M, Gulcelik MA, Uras C, Kocer HB, Soran A, Ibis K, Ozmen V. Cabioglu N, et al. Among authors: ibis k. Ann Surg Oncol. 2025 Feb;32(2):971-972. doi: 10.1245/s10434-024-16651-5. Epub 2024 Dec 9. Ann Surg Oncol. 2025. PMID: 39653946

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

36 results

Search Page

Filters